Compounds > ym 529
Page last updated: 2024-09-03

ym 529 and Kidney Neoplasms

ym 529 has been researched along with Kidney Neoplasms in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fukata, S; Fukuhara, H; Furihata, M; Inoue, K; Karashima, T; Kawada, C; Kurabayashi, A; Shuin, T1
Goto, H; Kanematsu, T; Miki, T; Muguruma, H; Sone, S; Uehara, H; Yano, S; Zhang, H1
Goto, H; Hanibuchi, M; Miki, T; Sone, S; Uehara, H; Yano, S; Zhang, H1
Kimura, S; Kuroda, J; Maekawa, T; Nogawa, M; Sato, K; Segawa, H; Yokota, A; Yuasa, T1

Other Studies

4 other study(ies) available for ym 529 and Kidney Neoplasms

ArticleYear
Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma.
    Cancer science, 2015, Volume: 106, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Cell Line, Tumor; Diphosphonates; Disease Progression; Humans; Imidazoles; Immunohistochemistry; In Situ Hybridization; In Situ Nick-End Labeling; Interferon-alpha; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Osteoclasts; Xenograft Model Antitumor Assays

2015
A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice.
    Clinical & experimental metastasis, 2003, Volume: 20, Issue:2

    Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Carcinoma, Small Cell; Cell Division; Cytokines; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Growth Factors; Humans; Imidazoles; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Lymphocyte Depletion; Lymphokines; Male; Mice; Mice, SCID; Osteolysis; Parathyroid Hormone-Related Protein; Peptide Hormones; Severe Combined Immunodeficiency; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2003
Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Nov-01, Volume: 9, Issue:14

    Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Carcinoma, Small Cell; Cell Division; Diphosphonates; Drug Combinations; Etoposide; Humans; Imidazoles; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, Inbred ICR; Mice, SCID; Osteoclasts; Parathyroid Hormone-Related Protein; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A

2003
A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jan-15, Volume: 11, Issue:2 Pt 1

    Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Proliferation; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; In Vitro Techniques; Interferon-alpha; Interferon-beta; Kidney Neoplasms; Luciferases; Mice; rap1 GTP-Binding Proteins; ras Proteins; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A

2005